Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Actinium PharmaceuticalsMereo BioPharma GroupCocrystal PharmaPhaseBio PharmaceuticalsChembio Diagnostics
SymbolNYSEAMERICAN:ATNMNASDAQ:MREONASDAQ:COCPNASDAQ:PHASNASDAQ:CEMI
Price Information
Current Price$7.38$3.29$1.19$3.05$3.82
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.51.41.41.51.3
Analysis Score3.53.53.53.53.2
Community Score3.22.22.92.32.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.00.80.0
Earnings & Valuation Score0.60.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$41.00$10.00$4.75$12.33$7.25
% Upside from Price Target455.56% upside203.95% upside299.16% upside304.37% upside89.79% upside
Trade Information
Market Cap$137.42 million$223.03 million$80.76 million$90.10 million$73.26 million
Beta1.231.691.461.852.05
Average Volume389,0702,343,9692,544,247581,8984,761,763
Sales & Book Value
Annual RevenueN/AN/A$6.56 million$2.36 million$34.46 million
Price / SalesN/AN/A12.9638.052.24
CashflowN/AN/A$0.99 per shareN/AN/A
Price / CashN/AN/A1.20N/AN/A
Book Value$1.03 per share$2.06 per share$0.73 per share$2.09 per share$1.37 per share
Price / BookN/AN/A1.631.462.79
Profitability
Net Income$-21,900,000.00$-44,490,000.00$-48,170,000.00$-39,250,000.00$-13,680,000.00
EPSN/A($2.49)($0.06)($1.43)($0.79)
Trailing P/E Ratio0.00N/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-2,938.09%N/A-76.55%
Return on Equity (ROE)-77.96%N/A-25.81%-220.57%-73.70%
Return on Assets (ROA)-64.62%N/A-23.98%-110.30%-33.21%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.60%N/A1.87%0.54%
Current Ratio10.51%2.99%12.59%4.39%4.07%
Quick Ratio10.51%N/A12.59%4.39%2.97%
Ownership Information
Institutional Ownership Percentage17.55%62.14%18.71%58.58%31.06%
Insider Ownership Percentage1.50%N/A10.80%17.00%3.00%
Miscellaneous
Employees30381350324
Shares Outstanding19.25 million67.79 million71.47 million29.44 million20.18 million
Next Earnings DateN/A6/30/2021 (Estimated)5/13/2021 (Estimated)5/11/2021 (Estimated)5/3/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Chembio Diagnostics, Inc. (NASDAQ:CEMI) Given Average Rating of "Hold" by AnalystsChembio Diagnostics, Inc. (NASDAQ:CEMI) Given Average Rating of "Hold" by Analysts
americanbankingnews.com - April 17 at 3:32 AM
Chembio Diagnostics Stock Is Believed To Be Modestly UndervaluedChembio Diagnostics Stock Is Believed To Be Modestly Undervalued
ca.finance.yahoo.com - April 15 at 2:34 PM
 Analysts Expect Chembio Diagnostics, Inc. (NASDAQ:CEMI) to Announce -$0.30 Earnings Per Share Analysts Expect Chembio Diagnostics, Inc. (NASDAQ:CEMI) to Announce -$0.30 Earnings Per Share
americanbankingnews.com - April 13 at 12:22 AM
If You Had Bought Chembio Diagnostics (NASDAQ:CEMI) Shares Three Years Ago You Would Be Down 39%If You Had Bought Chembio Diagnostics' (NASDAQ:CEMI) Shares Three Years Ago You Would Be Down 39%
finance.yahoo.com - April 7 at 8:35 AM
CEMI Stock News: Chembio Diagnostics Inc skyrockets 60% after FDA greenlights rapid covid/flu testsCEMI Stock News: Chembio Diagnostics Inc skyrockets 60% after FDA greenlights rapid covid/flu tests
fxstreet.com - April 6 at 9:05 AM
Chembio Jumps on Launch of Test Distinguishing COVID, FluChembio Jumps on Launch of Test Distinguishing COVID, Flu
finance.yahoo.com - April 5 at 6:38 PM
Chembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 testChembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 test
finance.yahoo.com - April 5 at 6:38 PM
Traders Buy High Volume of Chembio Diagnostics Call Options (NASDAQ:CEMI)Traders Buy High Volume of Chembio Diagnostics Call Options (NASDAQ:CEMI)
americanbankingnews.com - April 5 at 12:22 PM
CEMI Stock: Investors Cheer Commercial LaunchCEMI Stock: Investors Cheer Commercial Launch
cnafinance.com - April 5 at 8:37 AM
Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and FluChembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu
finance.yahoo.com - April 1 at 7:12 PM
Is this the best time to Buy Chembio Diagnostics, Inc. (NASDAQ:CEMI) stock?Is this the best time to Buy Chembio Diagnostics, Inc. (NASDAQ:CEMI) stock?
stocksregister.com - March 27 at 10:48 AM
Earnings Update: Heres Why Analysts Just Lifted Their Chembio Diagnostics, Inc. (NASDAQ:CEMI) Price Target To US$9.00Earnings Update: Here's Why Analysts Just Lifted Their Chembio Diagnostics, Inc. (NASDAQ:CEMI) Price Target To US$9.00
nasdaq.com - March 13 at 9:26 AM
Chembio Diagnosticss Earnings OutlookChembio Diagnostics's Earnings Outlook
benzinga.com - March 10 at 12:53 PM
Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of DirectorsChembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors
finance.yahoo.com - March 8 at 8:42 AM
Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
finance.yahoo.com - February 25 at 4:51 PM
Looking for a Top Momentum Stock? Check Out Chembio Diagnostics, Inc. (NASDAQ:CEMI)Looking for a Top Momentum Stock? Check Out Chembio Diagnostics, Inc. (NASDAQ:CEMI)
stocksregister.com - February 8 at 7:26 PM
Do Insiders Own Lots Of Shares In Chembio Diagnostics, Inc. (NASDAQ:CEMI)?Do Insiders Own Lots Of Shares In Chembio Diagnostics, Inc. (NASDAQ:CEMI)?
finance.yahoo.com - February 3 at 7:11 AM
CEMI Jan 2021 5.000 callCEMI Jan 2021 5.000 call
in.finance.yahoo.com - January 16 at 2:48 AM
CEMI Jan 2021 12.500 putCEMI Jan 2021 12.500 put
in.finance.yahoo.com - January 16 at 2:48 AM
Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test SystemsChembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems
finance.yahoo.com - January 14 at 5:45 PM
Chembio Diagnostics Appoints David Acheson, M.D. to its Board of DirectorsChembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors
finance.yahoo.com - December 17 at 7:34 PM
Roche CEO Says Testing Demand Could Outstrip Supply for MonthsRoche CEO Says Testing Demand Could Outstrip Supply for Months
baystreet.ca - December 17 at 9:33 AM
Is Chembio Diagnostics (NASDAQ:CEMI) Using Too Much Debt?Is Chembio Diagnostics (NASDAQ:CEMI) Using Too Much Debt?
finance.yahoo.com - December 5 at 6:24 PM
Stock Alert: Chembio Diagnostics Declines Following FDA ResponseStock Alert: Chembio Diagnostics Declines Following FDA Response
nasdaq.com - December 4 at 4:36 PM
Chembio Diagnostics (CEMI) Surges: Stock Moves 8.5% HigherChembio Diagnostics (CEMI) Surges: Stock Moves 8.5% Higher
finance.yahoo.com - December 3 at 9:25 AM
DateCompanyBrokerageAction
4/1/2021Actinium PharmaceuticalsHC WainwrightLower Price Target
12/31/2020Actinium PharmaceuticalsWilliam BlairReiterated Rating
11/5/2020Actinium PharmaceuticalsAlliance Global PartnersInitiated Coverage
8/21/2020Actinium PharmaceuticalsMaxim GroupReiterated Rating
2/26/2019Actinium PharmaceuticalsOppenheimerSet Price Target
12/4/2018Actinium PharmaceuticalsRoth CapitalSet Price Target
8/15/2018Actinium PharmaceuticalsB. RileySet Price Target
4/5/2021Mereo BioPharma GroupNeedham & Company LLCInitiated Coverage
10/10/2019Mereo BioPharma GroupSVB LeerinkReiterated Rating
11/18/2020Cocrystal PharmaNoble FinancialReiterated Rating
7/17/2018Cocrystal PharmaEuroPacific CanadaInitiated Coverage
3/18/2021PhaseBio PharmaceuticalsStifel NicolausReiterated Rating
8/25/2020PhaseBio PharmaceuticalsCitigroupLower Price Target
9/24/2019PhaseBio PharmaceuticalsCowenReiterated Rating
3/11/2021Chembio DiagnosticsColliers SecuritiesReiterated Rating
12/3/2020Chembio DiagnosticsCraig HallumUpgrade
6/17/2020Chembio DiagnosticsRobert W. BairdDowngrade
6/17/2020Chembio DiagnosticsBenchmarkDowngrade
6/17/2020Chembio DiagnosticsCanaccord GenuityDowngrade
12/19/2018Chembio DiagnosticsDougherty & CoInitiated Coverage
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.